ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
December 02, 2021 01:00 ET
|
ObsEva SA
GENEVA, Switzerland December 2, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today...
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
November 22, 2021 01:05 ET
|
ObsEva SA
FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA,...
ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo
October 20, 2021 01:00 ET
|
ObsEva SA
-Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster - Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss...
ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo
October 19, 2021 01:00 ET
|
ObsEva SA
–Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagolix for the treatment of severe adenomyosis– GENEVA,...
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
October 13, 2021 01:00 ET
|
ObsEva SA
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix -Linzagolix, an oral GnRH antagonist, is pending regulatory approval in the U.S. and Europe for the treatment of...
ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer
September 30, 2021 01:00 ET
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
September 15, 2021 01:00 ET
|
ObsEva SA
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids- -NDA submission includes positive data...
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
August 05, 2021 01:00 ET
|
ObsEva SA
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21- -Linzagolix for endometriosis:...
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty® (linzagolix) for the Treatment of Severe Adenomyosis at ESHRE Virtual 37th Annual Meeting
June 30, 2021 01:00 ET
|
ObsEva SA
-Two additional abstracts presented on data from ongoing clinical programs: Yselty for the treatment of uterine fibroids and nolasiban for uterine contractility of IVF patients prior to embryo...
ObsEva To Present Data on Two Clinical Development Programs at ESHRE Virtual 37th Annual Meeting
June 24, 2021 01:00 ET
|
ObsEva SA
- Data from Phase 3 study of Yselty® (linzagolix) for the treatment of uterine fibroids to be discussed in an oral presentation; Top-line data from pilot study of Yselty for the treatment of...